Cardiff Oncology (CRDF) Gains from Investment Securities (2023 - 2025)
Historic Gains from Investment Securities for Cardiff Oncology (CRDF) over the last 8 years, with Q3 2025 value amounting to $11.2 million.
- Cardiff Oncology's Gains from Investment Securities rose 3468.41% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.2 million, marking a year-over-year increase of 3468.41%. This contributed to the annual value of $8.3 million for FY2024, which is 2531.68% up from last year.
- Latest data reveals that Cardiff Oncology reported Gains from Investment Securities of $11.2 million as of Q3 2025, which was up 3468.41% from $11.7 million recorded in Q2 2025.
- In the past 5 years, Cardiff Oncology's Gains from Investment Securities registered a high of $11.7 million during Q2 2025, and its lowest value of $6.7 million during Q4 2023.
- For the 3-year period, Cardiff Oncology's Gains from Investment Securities averaged around $9.5 million, with its median value being $9.6 million (2024).
- Per our database at Business Quant, Cardiff Oncology's Gains from Investment Securities skyrocketed by 2531.68% in 2024 and then soared by 3468.41% in 2025.
- Quarter analysis of 3 years shows Cardiff Oncology's Gains from Investment Securities stood at $6.7 million in 2023, then grew by 25.32% to $8.3 million in 2024, then skyrocketed by 34.9% to $11.2 million in 2025.
- Its Gains from Investment Securities was $11.2 million in Q3 2025, compared to $11.7 million in Q2 2025 and $10.8 million in Q1 2025.